UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Curious about which cards offer the best rewards? Explore options that provide maximum benefits for your spending habits.
23,678 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Gold is leading gains in early 2026, while silver remains volatile. Analysts say the evolving ETF landscape is paving...
Investors weighed the promise of Milestone Pharmaceuticals against the realities of a high-stakes biotech market. Thi...
Nvidia CEO Jensen Huang reiterates a generous pay policy as AI-driven profits soar, highlighting how wealth from tech...
Dallas Wings star Azzi Fudd joins Project B, signaling a bold shift in how athletes monetize careers through a planne...
A fresh analysis shows WisdomTree's WCLD underperforms due to equal-weight rebalancing, turning a $10,000 stake into ...
Reese Witherspoon tells a Gen Z follower to chase talents, not dreams, in a viral moment. The message lands amid a 20...
A look at WWII-era weapons that helped allies reveals how innovation and mass production built a durable defense base...
A quartet of high-yield ETFs are now producing double-digit income in 2026, each using a different approach. Here's a...
Warren Buffett built wealth by buying durable businesses at fair prices. In this guide, we explore a Buffett-inspired...
Nextpower (NXT) 2026 earnings provide a window into the company’s growth engine and future trajectory. This piece bre...
The prospect of SpaceX going public has investors buzzing. History shows mega IPOs behave in patterns that can surpri...